4.4 Article

Nucleocapsid Antigenemia in Patients Receiving Anti-CD20 Therapy With Protracted COVID-19

期刊

OPEN FORUM INFECTIOUS DISEASES
卷 9, 期 8, 页码 -

出版社

OXFORD UNIV PRESS INC
DOI: 10.1093/ofid/ofac419

关键词

SARS-CoV-2; antigenemia; diagnostics; immunocompromised

资金

  1. NIH National Cancer Institute [1 U54 CA260563 01]
  2. NIH [U54 EB027690 03, UL1TR002378]
  3. Marcus Foundation

向作者/读者索取更多资源

Immunocompromised patients with prolonged coronavirus disease 2019 symptoms present diagnostic and therapeutic challenges. Nucleocapsid antigenemia can serve as a marker for persistent infection and therapeutic response in these patients, especially those treated with anti-CD20 immunotherapy.
Immunocompromised patients with prolonged coronavirus disease 2019 symptoms present diagnostic and therapeutic challenges. We measured viral nucleocapsid antigenemia in 3 patients treated with anti-CD20 immunotherapy who acquired severe acute respiratory syndrome coronavirus 2 infection and experienced protracted symptoms. Our results support nucleocapsid antigenemia as a marker of persistent infection and therapeutic response.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据